Haleon plc stock (GB00BMX86B70): Consumer health giant focuses on growth amid market shifts

Haleon plc, the leading consumer health company spun off from GSK, continues to prioritize oral care and pain relief segments. US investors track its performance on the London Stock Exchange for exposure to stable healthcare demand.

Haleon plc maintains its position as a key player in the global consumer health market, with brands like Sensodyne, Panadol, and Centrum driving sales. The company, which demerged from GlaxoSmithKline in 2022, reported steady performance in its latest filings, emphasizing resilience in everyday health products. This overview examines Haleon plc's business model and market dynamics for US retail investors.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Haleon plc
• Sector/industry: Consumer Health
• Headquarters/country: United Kingdom
• Core markets: North America, Europe, Emerging Markets
• Key revenue drivers: Oral care, Pain relief, Digestive health
• Home exchange/listing venue: London Stock Exchange (HLN)
• Trading currency: GBP

Haleon plc: core business model

Haleon plc operates as a pure-play consumer health company, focusing on over-the-counter products that address daily wellness needs. Its portfolio spans oral health, pain management, respiratory care, and nutritional supplements, sold through retail channels worldwide. The model relies on strong brand equity and innovation to maintain market share without prescription barriers.

Headquartered in Weybridge, UK, Haleon plc generates the majority of its revenue from established brands. Sensodyne leads in toothpaste for sensitive teeth, while Voltaren dominates topical pain relief. This direct-to-consumer approach provides defensive qualities, appealing to US investors seeking stability in healthcare amid economic volatility.

Main revenue and product drivers for Haleon plc

Oral care represents about 30% of Haleon plc's sales, powered by Sensodyne and Polident. Pain relief, including Panadol and Voltaren, contributes another 25%, with growth in gel formats. Digestive health products like Eno and digestive wellness items add diversification. In its full-year 2024 report published March 2025, Haleon plc posted net revenue of £2.75 billion for the period ended December 31, 2024, up 1.6% on a constant currency basis, according to Haleon IR as of 03/2025.

North America drives roughly 30% of revenue, benefiting from US market dominance in oral care. Emerging markets offer higher growth potential through affordable formats. Haleon plc invests in R&D, spending 2-3% of sales annually on product enhancements, supporting long-term margins around 18-20%.

Industry trends and competitive position

The consumer health sector grows at 4-6% annually, fueled by aging populations and self-care trends, per IQVIA reports as of 2025. Haleon plc holds top positions in multiple categories, competing with Procter & Gamble, Johnson & Johnson, and Reckitt. Its focused portfolio post-demerger allows agile responses to trends like natural ingredients and digital marketing.

In the US, Haleon plc's products reach consumers via Walmart, CVS, and Amazon, providing indirect exposure to American retail strength. The company's scale in supply chain management supports competitive pricing and availability.

Why Haleon plc matters for US investors

Haleon plc offers US investors access to a defensive consumer staple with global reach, listed as an ADR on OTC markets for easier trading. Its exposure to the robust US healthcare spend, projected at $4.5 trillion in 2025 by CMS data, aligns with portfolio diversification. Stable demand for OTC products weathers inflation better than discretionary goods.

Main revenue and product drivers for Haleon plc

Recent strategic moves include expanding Voltaren in the US with new formulations, boosting market penetration. Haleon plc's focus on sustainability, like recyclable packaging, resonates with ESG-conscious investors. For the 2024 period published in March 2025, like-for-like sales grew 2.8%, driven by volume in key markets.

Conclusion

Haleon plc stands as a resilient force in consumer health, with powerhouse brands fueling consistent revenue. While facing competition and currency risks, its strategic focus on innovation and core markets positions it well. US investors may find value in its defensive profile and US-centric growth drivers, warranting ongoing monitoring of quarterly updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.